Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.54 |
| ▸ | GPBAR1 | Q8TDU6 | 14/20 | 0.53 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.53 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.49 |
| ▸ | TOP2A | P11388 | 1/20 | 0.49 |
| ▸ | CES1 | P23141 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17832964 | 1.00 | SLC10A1 (0.54) | SLC10A1GPBAR1PRKCDNR1H4PTPN1 | |
| SCHEMBL476921 | 0.85 | SLC10A1 (0.73) | SLC10A1GPBAR1PRKCDNR1H4PTPN1 | |
| SCHEMBL13384623 | 0.85 | SLC10A1 (0.73) | SLC10A1GPBAR1PRKCDNR1H4PTPN1 | |
| SCHEMBL13403268 | 0.85 | SLC10A1 (0.73) | SLC10A1GPBAR1PRKCDNR1H4PTPN1 | |
| SCHEMBL476920 | 0.85 | SLC10A1 (0.73) | SLC10A1GPBAR1PRKCDNR1H4PTPN1 | |
| SCHEMBL17817073 | 0.85 | SLC10A1 (0.55) | SLC10A1GPBAR1PRKCDNR1H4PTPN1 | |
| SCHEMBL24104641 | 0.85 | SLC10A1 (0.42) | SLC10A1GPBAR1PRKCDNR1H4PTPN1 | |
| SCHEMBL17832966 | 0.85 | PTPN1 (0.52) | SLC10A1GPBAR1PRKCDPTPN1CES2 | |
| SCHEMBL17817298 | 0.84 | SLC10A1 (0.60) | SLC10A1GPBAR1PRKCDNR1H4 | |
| SCHEMBL17832965 | 0.84 | SLC10A1 (0.60) | SLC10A1GPBAR1PRKCDNR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3229811-B1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | GRI BIO INC (US) | 2021-02-24 | — | — | EP | disclosed |
| WO-2016094226-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | GLYCOREGIMMUNE, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | ALTIUM GROWTH FUND, LP | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | RXRA, RXRG, CX3CR1 | SLC10A1 1776/4885GPBAR1 757/4885PRKCD 1223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.